Human Epidermal Growth Factor Receptor 2 Negative

• HER2-negative status indicates cancer cells do not have an excess of the HER2 protein.
• This classification is vital for tailoring effective cancer treatments, as HER2-targeted therapies are not effective.
• HER2-negative breast cancer is a common subtype, accounting for about 70-80% of all breast cancers.
• Treatment typically involves chemotherapy, hormone therapy (if hormone receptor-positive), surgery, and sometimes immunotherapy.
• Prognosis varies but is generally favorable for early-stage HER2-negative disease, though specific subtypes have different outcomes.

What is Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative)?

Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) describes cancer cells that do not produce an excessive amount of the HER2 protein on their surface. The HER2 protein is a receptor that plays a role in cell growth, division, and repair. When cancer cells have too many HER2 receptors, they are considered HER2-positive, which can lead to more aggressive cancer growth. Conversely, when cells are classified as HER2-negative, it means they do not have this overexpression, and their growth is not primarily driven by the HER2 pathway. This distinction is critical because it dictates whether certain targeted therapies, which specifically block the HER2 protein, will be effective.

HER2-Negative Breast Cancer: Meaning and Diagnosis

The HER2 negative breast cancer meaning signifies that the tumor cells do not overexpress the HER2 protein. This makes it distinct from HER2-positive breast cancer, which often grows and spreads more aggressively. Approximately 70-80% of all breast cancers are classified as HER2-negative, according to the American Cancer Society. This broad category includes several subtypes, such as hormone receptor-positive (estrogen receptor-positive and/or progesterone receptor-positive) and triple-negative breast cancer (negative for HER2, estrogen receptor, and progesterone receptor).

Diagnosis of HER2 status typically involves laboratory tests performed on a tissue sample obtained during a biopsy or surgery. The primary methods used are:

• Immunohistochemistry (IHC): This test uses antibodies to detect the HER2 protein on the surface of cancer cells. Results are scored from 0 to 3+. A score of 0 or 1+ is considered HER2-negative.
• Fluorescence In Situ Hybridization (FISH): If IHC results are equivocal (2+), FISH is often used. This test looks for extra copies of the HER2 gene within the cancer cells. If no extra copies are found, the cancer is HER2-negative.

Accurate HER2 testing is crucial for guiding treatment decisions, as HER2-targeted therapies are only effective for HER2-positive cancers.

Treatment and Prognosis for HER2-Negative Cancer

Treatment for HER2 negative cancer is tailored based on the specific subtype and stage of the disease, as well as other factors like hormone receptor status. Since HER2-negative cancers do not respond to HER2-targeted therapies, treatment typically focuses on other approaches. For HER2-negative breast cancer, common treatment modalities include:

• Surgery: To remove the tumor, often followed by radiation therapy to eliminate any remaining cancer cells in the breast area.
• Chemotherapy: Systemic treatment that uses drugs to kill cancer cells throughout the body. This is a cornerstone for many HER2-negative cancers, especially triple-negative breast cancer.
• Hormone Therapy: If the cancer is also hormone receptor-positive (e.g., estrogen receptor-positive), hormone-blocking drugs are used to prevent cancer cells from receiving signals that promote growth.
• Immunotherapy: For certain aggressive subtypes like triple-negative breast cancer, immunotherapy drugs may be used, often in combination with chemotherapy, to help the body’s immune system fight the cancer.

The prognosis of HER2 negative disease varies significantly depending on the specific subtype, stage at diagnosis, and response to treatment. For early-stage HER2-negative breast cancer, the prognosis is generally favorable, especially for hormone receptor-positive subtypes. Triple-negative breast cancer, while also HER2-negative, can be more aggressive and has a higher risk of recurrence, particularly in the early years after diagnosis. However, advancements in chemotherapy and the introduction of immunotherapy have improved outcomes for these patients. Regular follow-up and adherence to treatment plans are essential for managing HER2-negative cancers and improving long-term outcomes.